EVAXION A/S
EVAXNASDAQTrading Snapshot
- Day Range
- $416.55 – $422.44
- 52-Week Range
- —
- Volume
- $3.43B
- Avg Volume
- $4.48B
- Shares Outstanding
- —
- Next Earnings
- Sep 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $18.56B
- Last Q Revenue
- $4.55B
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own EVAX
- ✓High-growth profile — revenue up -0.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 44% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About EVAXION A/S
A company profile for EVAXION A/S isn’t available yet — check back soon.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Merek & Company 13F Filing Shows Co Reported 1.214M-Share Position In Evaxion Valued At $3.76M
https://www.sec.gov/Archives/edgar/data/310158/000031015826000210/xslForm13F_X02/MerckInformationTableQ2.xml
Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026
Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune responseData will also offer insight into the vaccine’s effect also as stand-alone treatment of patients with advanced melanomaUnprecedented two-year data from the trial presented last year showed high response rates and an impressive durability of responses COPENHAGEN, Denmark, July 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinic
Evaxion To Present 3-Yr Clinical Efficacy Data From Phase 2 Trial With Personalized Cancer Vaccine Candidate EVX-01 At ESMO Congress 2026
Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune responseData will also offer insight into the vaccine’s effect
Reported Sunday, Evaxion Presents New Preclinical Data Showing Multi-Component EVX-V1 Vaccine Pairs AI-Discovered Antigens With AI-Optimized Antigens To Target CMV From Multiple Angles
The new data demonstrates the potential to improve control of acute infection, latency, and viral reactivation, further supporting the concept behind EVX-V1EVX-V1 is a next-generation, multi-component vaccine program